Introduction
============

Breast cancer is a major public health problem for women throughout the world. In the United States, breast cancer remains the most common cancer in women and the second most frequent cause of cancer death \[[@ref1]\]. Breast cancer is the most frequently diagnosed cancer in Pakistani females \[[@ref2]\]. Breast cancer has been found to constitute 33% of all cancers in females registered at the Nuclear Medicine, Oncology and Radiotherapy Institute (NORI) Islamabad \[[@ref3]\]. There are a number of factors which determine the prognosis of disease and response to treatment. Prognostic factors are those which determine the outcome of disease in the absence of systemic treatment whereas predictive factors predict response to treatment \[[@ref1]\]. Estrogen receptor (ER) and progesterone receptor (PR) expressions are the most important and useful predictive factors currently available. ER and PR are intracellular steroid hormone receptors which have received substantial attention since 1986. Measurable amounts of ER and PR are found in about 50--85% of patients with breast cancer. The frequency of positivity and the level of ER and PR increase with age, reaching their highest levels in postmenopausal women \[[@ref4]\]. Men have a higher ER and PR expression as compared to female breast cancer patients without any association with histological prognostic markers \[[@ref5]\].

Her 2 Neu gene amplification is another important prognostic and predictive factor for breast cancer. Approximately 20% of breast cancer patients have Her 2 Neu gene amplification which results in glycoprotein overexpression \[[@ref1]\]. This oncogene is associated with tumour aggressiveness and chemoresistance \[[@ref6]\]. Her 2 Neu is an important factor in predicting response to trastuzumab. Only Her 2 Neu positive breast cancer cases are responsive to this drug \[[@ref7]\]. A number of studies have been performed internationally showing the frequency of ER, PR, and Her 2 Neu positivity in breast cancer and their prognostic and predictive significance. Generally, the frequency of receptor positivity is inversely correlated with Her 2 Neu \[[@ref8]--[@ref10]\]. ER, PR negativity, and Her 2 Neu positivity have been found to be associated with higher tumour grade, larger tumour size, higher degree of lymph node involvement, and aggressive histopathological type \[[@ref11]\].

Contrary to Europe and America, in Pakistan more than 60% of breast cancer patients present at an advanced stage of the disease. This means the biological behaviour of breast cancer in Pakistani population is different. Very few studies have been done in the country to find out the clinicopathological significance of ER, PR, and Her 2 Neu. Oncology patients from Northern Pakistan which include the twin cities of Rawalpindi, Islamabad, upper Punjab, Khyber Pakhtunkhwa, Gilgit Baltistan, Kashmir, and Hazara attend NORI. This study was carried out to note the frequency of positivity of ER, PR, and Her 2 Neu and its association with menopausal status, and tumour-related characteristics in addition to recurrent disease and overall survival in breast cancer cohort from Northern Pakistan, registered at the NORI Hospital, Islamabad.

Methodology
===========

This observational study was conducted in the Oncology Department of Nuclear Medicine, Oncology & Radiotherapy Institute (NORI), Islamabad, after review and approval by the Institutional Ethics Review Committee. Patients attending NORI with a histopathologically proven diagnosis of invasive ductal carcinoma of the breast were included consecutively from January 2006 to December 2009 after providing informed consent. The status of ER, PR, and Her 2 Neu was sought by immunohistochemistry, and the presence of Her 2 Neu oncogene was confirmed by the Fluorescent In situ Hybridization (FISH) technique in each patient.

Age, menopausal status, tumour size, and the presence or absence of nodal involvement (including site and number), distant metastases, sites of metastases, skin involvement, chest wall involvement, recurrent disease, and bilateral breast cancer were noted along with ER, PR, and Her 2 Neu status on a specifically designed *pro forma*. Mean ± standard deviation was calculated for continuous variables like age. The frequency and percentage were calculated for categorical variables like ER, PR, and Her 2 Neu status. The association of ER, PR, and Her 2 Neu status with menopausal status and tumour-related characteristics was sought employing *t*test, *x*^2^square test, and ANOVA wherever appropriate. *P* value \>0.05 was considered significant.

Results
=======

There were 1,511 breast cancer patients that attended NORI during the study period. The ER, PR, and Her 2 Neu status of 285 of the patients could not be retrieved at the time of study compilation and these patients were excluded. The study thus comprised 1,226 patients.

The mean patient age was 48.04 ± 11.97 years. Regarding menopausal status, 743 (60.6%) patients were premenopausal and the rest postmenopausal. There were 881 (71.9%) patients who had T3 tumours, i.e. \>5 cm in size. Skin and chest wall involvement were observed in 460 (37.5%) and 197 (16.1%) patients, respectively. There were 990 (80.8%) patients who had lymph node positive disease. The frequency of the number of positive axillary lymph nodes is given in [Table 1](#table1){ref-type="table"}. Supraclavicular nodes were involved in 108 (8.8%) patients. There were 274 (22.3%) patients who presented with distant metastases. The most common site of distant metastases were bone (*n*= 202, 16.5%), followed by lung (*n*= 163, 13.3%), liver (*n*= 98, 8%), and brain (*n*= 27, 2.2%). One patient (0.1%) had omental deposits. Recurrent disease was noted in 237 (19.3%) patients. Fifty four (4.4%) patients had bilateral breast cancer.

The frequency and percentage of patients with positive ER, PR, and Her 2 Neu are given in [Table 2](#table2){ref-type="table"}. Correlation of expression of ER, PR, and Her 2 Neu with menopausal status, tumour size, skin and chest wall involvement, nodal involvement, number of nodes involved, distant metastases, bilateral breast cancer, and recurrent disease is shown in [Table 3](#table3){ref-type="table"}. Significant association (*P*\< 0.05) was detected between ER, PR status, and Her 2 Neu expression ([Table 4](#table4){ref-type="table"}).

Discussion
==========

Prognostic and predictive factors are universally utilized in the management of breast cancer and can be used to stratify patients into two groups; those who are expected to derive the most benefit from adjuvant systemic therapy and those for whom the risks and costs of adjuvant therapy outweigh the expected benefit \[[@ref12]\]. ER/PR status and Her 2 Neu gene amplification and/or overexpression are both prognostic and predictive. Generally, ER and PR positivity and Her 2 Neu gene negativity are associated with better prognosis and vice versa.

The present study was carried out to determine the frequency of ER, PR, and Her 2 Neu positivity and correlation of expression of ER, PR, and Her 2 Neu with menopausal status and some pathological parameters, as well as their effect on recurrence rate and overall survival in breast cancer patients registered at NORI from Northern Pakistan. The results obtained were found to be more or less similar to those reported in the international literature with some exceptions. The mean age of the patients in the study conducted was 48.04 years, and 42.4% patients were in 4th decade of life. The youngest patient seen was 19 years old. This age distribution is significantly younger than what is currently seen in western and Arab countries \[[@ref13], [@ref14]\]. More studies are required to determine the predisposing factors in our patients. One possible explanation is that cousin marriages are very common in Pakistan and accordingly hereditary factors could play a role. Another factor could be the degree of obesity associated with a diet high in fat and carbohydrates and lack of physical activity.

In the study conducted, ER and PR were found to be positive in 62.2 and 60.1% patients, respectively, whereas Her 2 Neu was positive in 38.9%. These figures are different from those reported in a series of 112 patients (ER positive 72.3% and Her 2 positive 11.6%) \[[@ref15]\]. This study was conducted in a small number of patients, i.e. 112 and patient demographics were different.

Correlation of ER, PR with Her 2 Neu showed inverse relationship in the study conducted. The percentage of patients with positive ER and PR was found to be low in Her 2 Neu positive patients (18.35%) and high in Her 2 Neu negative patients (43.31%). The same results have been reported by Farzami *et al*\[[@ref16]\] who found that Her 2 Neu overexpression was higher in ER and PR negative cases than ER and PR positive patients. As reported in literature higher number of ER and PR positive patients were postmenopausal with *P*value \<0.05, whereas overexpression of Her 2 Neu was found to be significantly high in premenopausal women (*P*\< 0.05) in our study. A significantly high mean (*P*\< 0.05) of ER and PR positively stained cells was observed in postmenopausal females compared to premenopausal women, and Her 2 Neu overexpression was seen only in premenopausal women in a study done by Hussein *et al*\[[@ref17]\].

In our patients, a very strong association was also detected between ER, PR, and Her 2 Neu expression and menopausal status and pathological parameters including tumour size, involvement of skin, chest wall and lymph nodes and the presence of supraclavicular adenopathy and distant metastases (*P*\< 0.05). ER, PR negativity, and Her 2 Neu positivity was found to be associated with worsening disease stage i.e. increasing tumour size, increased involvement of skin, chest wall, lymph nodes, and the presence of distant metastases. The same results have been reported in other studies \[[@ref18]--[@ref21]\]. However, such a significant association of PR and Her 2 Neu was not detected with the presence of bilateral breast cancer. In our study, the grade of the tumour and response to treatment could not be studied although the grade of the tumour is affected by receptor status and Her 2 Neu expression \[[@ref22]--[@ref25]\]. Moreover, significant association of ER, PR, and Her 2 Neu with recurrent disease could not be detected which is contrary to the international literature \[[@ref18]--[@ref21]\].

More extensive studies are required to assess response to treatment and survival benefit in both receptor positive and negative patients. To make national guidelines for treatment, the studies should cover the population from all over the country. We should be able to identify early stage ER, PR, and Her 2 positive breast cancer in order to achieve improved disease control and overall survival of Pakistani women with a breast cancer diagnosis.

Conclusions
===========

The frequency of expression of hormonal receptors in breast cancer patients from Northern Pakistan is the same as reported in the literature although overexpression of Her 2 Neu is higher in our population. There is an inverse relationship between hormonal receptors expression and Her 2 Neu expression. Postmenopausal women have a higher incidence of ER and PR positivity and Her 2 Neu negativity. ER and PR negativity and Her 2 Neu positivity are associated with more advanced disease and poor outcome.

###### Number of nodes involved.

  No. of nodes involved   No of patients   Percent
  ----------------------- ---------------- ---------
  1--4                    320              26.1
  5--9                    400              32.6
  10--20                  206              16.8
  \>20                    64               5.2
  No nodes involved       236              19.2
  Total                   1226             100.0

###### Frequency and percentage of ER, PR, & Her 2 Neu.

  Status     No. and percentage of patients with ER status   No. and percentage of patients with PR status   No. and percentage of patients with Her 2 Neu expression
  ---------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------------------
  Positive   763 (62.2%)                                     738 (60.1%)                                     478 (38.9%)
  Negative   463 (37.8%)                                     488 (39.8%)                                     748 (61.01%)

###### Correlation of expression of ER, PR, & Her 2 Neu with different parameters.

  Parameter                                Status of ER (*P*value)   Status of PR (*P*value)   Status of Her 2 Neu (*P*value)         
  -------------------------- ------------- ------------------------- ------------------------- -------------------------------- ----- -----
  Menopause                                                                                                                           
  Present                    345           138                       326                       157                              160   321
  Absent                     418           325                       412                       331                              318   427
                             (0.0000001)   (0.00007381)              (0.0008864)                                                      
  Tumour size                                                                                                                         
  Up to 2 cm                 22            12                        21                        13                               16    21
  \>2--5 cm                  219           92                        202                       109                              109   196
  \>5 cm                     522           359                       515                       366                              353   531
                             (0.002147)    (0.3383)                  (0.0000001)                                                      
  Skin involvement                                                                                                                    
  Present                    231           229                       229                       232                              232   235
  Absent                     532           234                       510                       256                              246   513
                             (0.0000001)   (0.0000001)               (0.0000001)                                                      
  Chest wall involvement                                                                                                              
  Present                    88            109                       77                        120                              91    114
  Absent                     675           354                       661                       366                              387   634
                             (0.0000001)   (0.0000001)               (0.1142)                                                         
  Nodal involvement                                                                                                                   
  Present                    601           389                       587                       403                              412   578
  Absent                     162           74                        151                       85                               66    170
                             (0.0382)      (0.3644)                  (0.000004874)                                                    
  Number of nodes involved                                                                                                            
  1--4                       219           101                       225                       109                              107   215
  5--9                       257           153                       256                       144                              168   226
  10--20                     100           126                       102                       108                              105   99
  \>20                       30            34                        63                        59                               53    100
  Supraclavicular nodes                                                                                                               
  Present                    35            73                        36                        72                               69    48
  Absent                     728           390                       702                       416                              409   700
                             (0.0000001)   (0.0000001)               (0.000004513)                                                    
  Distant metastases                                                                                                                  
  Present                    119           155                       118                       156                              150   132
  Absent                     644           308                       620                       332                              328   616
                             (0.0000001)   (0.0000001)               (0.0000001)                                                      
  Bilateral breast cancer                                                                                                             
  Present                    26            28                        29                        25                               23    39
  Absent                     737           435                       709                       463                              455   709
                             (0.02897)     (0.5974)                  (0.8598)                                                         
  Recurrence                                                                                                                          
  Present                    136           101                       130                       107                              104   141
  Absent                     626           362                       608                       381                              374   607
                             (0.1727)      (0.3640)                  (0.3581)                                                         

###### Relationship of Her 2 Neu expression with ER and PR status.

  Her 2 expression   Status of ER (*P*value)   Status of PR (*P*value)         
  ------------------ ------------------------- ------------------------- ----- -----
  Her 2 positive     225                       253                       227   251
  Her 2 Negative     531                       217                       504   244
                     (0.0000001)               (0.0000001)                     
